### **Overview** Sigachi Industries Limited, founded in 1989 and headquartered in Hyderabad, Telangana, is a publicly listed (NSE/BSE) specialty chemicals and pharmaceutical ingredients company with over 36 years of industry leadership. It has evolved from a microcrystalline cellulose (MCC) manufacturer into a diversified global player with integrated operations across **pharmaceutical excipients, Active Pharmaceutical Ingredients (APIs), nutraceuticals, food & nutrition, and Operations & Maintenance (O&M) services**. The company operates in over 65 countries through a robust global network, serving pharmaceutical, nutraceutical, food, cosmetic, and industrial customers. --- ### **Core Business Segments** 1. **Excipients** - **Global Leader in Microcrystalline Cellulose (MCC):** Sigachi is one of the world’s largest producers and India’s leading manufacturer of MCC, with ~22,000 MTPA production capacity across facilities in Dahej (Gujarat), Jhagadia (Gujarat), and Hyderabad (Telangana). - **Product Portfolio:** Offers over 60 grades of MCC (particle size: 15–250 microns) sold under branded names **HiCel™, AceCel®, CoatCel®, GloCel®, and BARETab®**. Products are used as binders, disintegrants, and stabilizers in solid oral dosage forms, food, nutraceuticals, and cosmetics. - **Portfolio Diversification:** Expanding into **pre-formulated, co-processed excipients**, and **Croscarmellose Sodium (CCS)**, with a new 1,800 MTPA CCS facility under construction at Dahej SEZ, expected to be operational by October 2026. 2. **Active Pharmaceutical Ingredients (APIs) & Intermediates** - **Strategic Entry via Trimax Acquisition:** In 2023, Sigachi acquired 80% of **Trimax BioSciences Pvt Ltd**, a USFDA and WHO-GMP compliant API manufacturer in Raichur, Karnataka. This acquisition enables vertical integration and access to a shared customer base in the pharmaceutical sector. - **Capacity Expansion:** API production capacity is being scaled from 100 KL to **250 KL**, expected to be operational by January 2026. The expanded unit will serve as a centralized hub for API development and analytics. - **Regulatory Advancement:** Multiple **Certificate of Suitability (CEP)** filings are in progress, including approved **Metformin HCl** and pending **Propafenone Hydrochloride** (expected imminently). Six additional CEPs are targeted, aiming to establish a foothold in regulated markets (EU, US). - **Revenue Target:** API segment expected to grow from 8% to **20–25% of total revenue** in the next 2–3 years. 3. **Nutraceuticals & Human Nutrition** - **Product Offerings:** Expanded into **vitamin-mineral premixes** (BaseBlend), nutraceutical coatings (PureCoat, UltraMod), spray-dried ingredients, and microencapsulated formulations. - **Applications:** Supports dietary supplements, food fortification (e.g., “with added calcium/zinc”), functional foods, and ready-to-use blends for bakery, dairy, and infant nutrition. - **Market Focus:** Targets B2B sales in India and export markets (60+ countries), serving private labels and food manufacturers. A dedicated manufacturing facility in Sultanpur (GAIN-approved) enhances nutritional product compliance. 4. **Operations & Maintenance (O&M) Services** - **Asset-Light Model:** Provides comprehensive O&M for chemical, petrochemical, water treatment, and pharmaceutical plants with **zero capital expenditure**, ensuring high returns on equity. - **Key Clients:** Contracts with **Gujarat Alkalies, Aditya Birla Group, ONGC, Adani Solar, and Lords Chloro Alkali**. These operations are expanding into turnkey management and plant outsourcing, especially in the Middle East. - **Growth Driver:** Stable and scalable revenue stream, contributing ~10% of total turnover. --- ### **Expansion & Strategic Growth Initiatives** #### **Geographical Expansion** - **Middle East Focus:** Sigachi has established a strong regional footprint via: - **Sigachi MENA FZCO** (Dubai-based, wholly owned subsidiary). - **Sigachi Arabia** (75:25 JV with Saudi National Projects Investment Ltd) targeting Saudi government tenders and GCC expansion. - **Planned Manufacturing Facility in Riyadh (Saudi Arabia)** within the next three years to localize production. - **North America:** Presence through **Sigachi Inc. (USA)**, reducing freight costs and lead times. Future US manufacturing facility planned to further penetrate the North American market. - **Emerging Markets:** Targeting Latin America, Southeast Asia, and Africa, with distribution alliances and turnkey O&M contracts. #### **Capacity & Infrastructure** - **MCC Capacity:** 22,000 MTPA (~80% utilization projected by Q4 FY26). Potential to scale to **25,000 MTPA** with minimal additional capex. - **Dahej SEZ Hub:** A key manufacturing and export center with USFDA, EXCiPACT GMP, WHO GMP, HACCP, and ISO certifications—enabling access to regulated markets. - **CCS Project:** 1,800 MTPA Croscarmellose Sodium facility in Dahej with environmental clearance; targets commercialization by FY26. #### **Innovation & R&D** - **Hyderabad API R&D Center:** Fully operational as of July 2025, consolidating end-to-end API development, analytical functions, and global regulatory submissions. Investment up to **USD 1 million**, with a dedicated R&D team of 15–20 scientists. - **R&D Spend:** ₹66.04 crore in FY25; two DSIR-accredited laboratories (Dahej and Hyderabad). - **Patents & IP:** 7 granted patents in cellulose and excipient technologies, and 46 trademarks. Focus on nano-cellulose, biorefinery from agricultural waste, and advanced drug delivery. - **"Ask an Expert" Platform:** Enhances customer engagement and technical support. --- ### **Recent Financial Performance (FY2025)** - **MCC Segment (Core):** Revenue of **₹409 crores** (+35.75% YoY). - **API Segment:** Revenue of **₹29 crores**, expected to grow rapidly post-scale-up and approvals. - **O&M Segment:** Revenue of **₹41 crores** (+17.66% YoY). - **H1 FY25 Total Income:** ₹2,369.29 million (+26.96% YoY). - **Capacity Utilization:** High utilization at MCC facilities; growing momentum in API and coatings. --- ### **New Product Launches & Innovation** - **PureCoat® and UltraMod™:** Proprietary pharmaceutical film coating brands launched in FY25 to improve **drug stability, bioavailability, and patient compliance**. - **Coating Market Entry:** Targets **16–18% market share in India** within three years; leverages synergies from Dahej MCC expansion. - **BaseBlend Series:** Vitamin-mineral premixes launched for nutraceutical, food, and cosmetic applications, targeting the growing **global premix market**. --- ### **Sustainability & ESG** - **Sustainable Sourcing:** Relies on imported refined wood pulp (Switzerland, USA, Canada, etc.). 70% under fixed-price contracts for stability. - **Environmental Initiatives:** Novel filtration process for MCC; sustainable packaging; biorefinery use of agricultural waste. - **ESG Compliance:** **98% ESG compliance across supplier base**, 100% sustainable packaging processing—enhancing appeal in regulated, environmentally conscious markets. --- ### **Key Strategic Partnerships** - **Respilon Group s.r.o.:** MOU signed (April 2025) to co-develop **non-invasive drug delivery systems** using NUENEX® nanofiber technology for invisible patches and powders. - **Joint Ventures:** - **Sigachi Global** (75:25 with iConsult Trading, UAE) – targets UAE pharma and food markets. - **Sigachi Arabia** (75:25 with SNP Global) – leverages local government access and corporate contracts.